Canada's Cipher Pharmaceuticals Q4 net income rises
Overview
Canada specialty pharma firm's Q4 net income rose yr/yr
Adjusted EBITDA for Q4 rose 40% yr/yr
Outlook
Cipher expects to drive market share growth for Natroba™ in the U.S. anti-parasitic market
Company aims to obtain Health Canada approval for Natroba™ and commercialize it in Canada
Cipher plans to pursue acquisitions and out-licensing Natroba™ globally in regions with high unmet need
Result Drivers
NATROBA PERFORMANCE - Co said additional operating income from U.S. business led by Natroba drove Q4 results
HIGHER GROSS MARGIN - Gross margin rose to 81%, driven by absence of prior-year non-cash inventory adjustments and strong Natroba margins
Company press release: ID:nCNW2lbGMa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Income |
| $13.3 mln |
|
Q4 Adjusted EBITDA | Beat | $6.97 mln | $5.87 mln (2 Analysts) |
Q4 EBITDA |
| $6.53 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Cipher Pharmaceuticals Inc is C$19.00, about 31.6% above its March 11 closing price of C$14.44
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 18 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
